Who owns XENE? 13F holders and whale ownership
XENE is tracked across public portfolios in Whale Analyzer. This page answers who owns XENE, which top funds are buying XENE, aggregate disclosed value, and recent position changes based on public data. Samuel Isaly is the largest reported holder at $62M; the top five funds control 100.0% of reported ownership; institutions were net buying last quarter (2 increased, 0 reduced); the stock trades above the aggregate whale cost basis of $41.01. Top tracked holders include Samuel Isaly, Baker Bros. Advisors, and Stanley Druckenmiller.
Continue to the live XENE dashboardTop holders
| Investor | Reported value | Shares | Change |
|---|---|---|---|
| Samuel Isaly 13F portfolio OrbiMed Advisors holdings | $61.6M | 1.1M | Increased |
| Baker Bros. Advisors 13F portfolio Baker Bros. Advisors holdings | $21.5M | 370.2K | Held |
| Stanley Druckenmiller 13F portfolio Duquesne Family Office holdings | $13.9M | 238.6K | New |
Ownership concentration
Reported ownership of XENE is highly concentrated across tracked institutions.
- Single largest holder: 63.5% of reported ownership
- Top 5 holders: 100.0%
- Top 10 holders: 100.0%
Whale activity this quarter
Across 3 tracked institutions, 2 increased, 1 held. Net positioning is net buying.
- Samuel Isaly — OrbiMed Advisors ($61.6M) (▲ 137.0% qoq shares)
- Baker Bros. Advisors — Baker Bros. Advisors ($21.5M) (→ 0.0% qoq shares)
- Stanley Druckenmiller — Duquesne Family Office ($13.9M) · avg cost $41.01
Whale cost basis vs current price
The aggregate tracked cost basis is $41.01 versus a current price of $59.74, so XENE trades above its cost basis (+45.7%). Average unrealized P&L across tracked holders: 33%.
Sector positioning — Health Care
XENE sits within the Health Care sector alongside 221 other tracked names. Compare whale ownership across peers:
How to use this page
Values are reported public positions from tracked 13F filers and disclosures — not real-time ownership totals. Open the live XENE dashboard for price charts and cross-investor scans, or read the SEC 13F guide.
Related stock holder pages
- EWTX whale holders — EDGEWISE THERAPEUTICS INC
- ELVN whale holders — ENLIVEN THERAPEUTICS INC
- LLY whale holders — ELI LILLY & CO
- SVA whale holders — SINOVAC BIOTECH LTD
- BSX whale holders — BOSTON SCIENTIFIC CORP
- SION whale holders — SIONNA THERAPEUTICS INC
- AZN whale holders — ASTRAZENECA PLC
- MYGN whale holders — MYRIAD GENETICS INC
Learn more in Whale Analyzer Academy
Deepen your read on XENE with these Whale Analyzer Academy guides:
Frequently asked questions
Who owns XENE stock?
Whale Analyzer tracks 3 public institutional holders of XENE with a combined reported value of $97.0M. See the holder table above for the largest tracked positions.
Which top funds are buying XENE?
Tracked institutions were net buying last quarter — 2 increased, 1 held. Check the "Change" column: "New" = fresh position, "Increased" = added, "Reduced" = trimmed.
How concentrated is XENE ownership?
The top five tracked holders report 100.0% of aggregate ownership.
Is XENE above or below the whale cost basis?
The aggregate tracked cost basis is $41.01 versus a current price of $59.74 (+45.7%).
What does 13F ownership mean for XENE?
Use the interactive XENE dashboard on Whale Analyzer for real-time holder analysis, or read our 13F Alpha Signals Guide.